转移性-话题@MedSci

#转移性#

975篇内容 | 3334人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1387012, encodeId=84c7138e012d0, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Gastroenterology Report：术前CA125升高与接受原发性肿瘤切除的转移性结直肠癌患者的低生存率相关, objectType=article, longId=732677, objectId=e228e3267764, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e228e3267764, replyNumber=0, likeNumber=88, createdTime=2022-07-19, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e228e3267764, moduleTitle=Gastroenterology Report：术前CA125升高与接受原发性肿瘤切除的转移性结直肠癌患者的低生存率相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e228e3267764)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387011, encodeId=74e5138e0110b, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Eur Urol Oncol：雄激素剥夺疗法联合根治性局部治疗与单独的雄激素剥夺疗法治疗新诊断寡转移性前列腺癌的疗效比较 , objectType=article, longId=732585, objectId=c18be325856d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c18be325856d, replyNumber=0, likeNumber=81, createdTime=2022-07-18, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c18be325856d, moduleTitle=Eur Urol Oncol：雄激素剥夺疗法联合根治性局部治疗与单独的雄激素剥夺疗法治疗新诊断寡转移性前列腺癌的疗效比较 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c18be325856d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387010, encodeId=bcd1138e010e3, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Radiology：CT和CA19-9对非转移性胰腺癌治疗效果的评估, objectType=article, longId=731928, objectId=fea2e3192803, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fea2e3192803, replyNumber=0, likeNumber=83, createdTime=2022-07-11, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fea2e3192803, moduleTitle=Radiology：CT和CA19-9对非转移性胰腺癌治疗效果的评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fea2e3192803)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387009, encodeId=a219138e009d2, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=J Immunother Cancer：抗PD1±抗CTLA4治疗BRAF/MEK抑制剂治疗失败的V600BRAF突变型转移性黑色素瘤, objectType=article, longId=731840, objectId=fa30e31840a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa30e31840a0, replyNumber=0, likeNumber=92, createdTime=2022-07-10, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa30e31840a0, moduleTitle=J Immunother Cancer：抗PD1±抗CTLA4治疗BRAF/MEK抑制剂治疗失败的V600BRAF突变型转移性黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa30e31840a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387008, encodeId=4e66138e00858, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Int J Clin Oncol：前期接受醋酸阿比特龙和多西他赛治疗的转移性去势敏感前列腺癌患者的真实结果和风险分层 , objectType=article, longId=730534, objectId=206be305347e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=206be305347e, replyNumber=0, likeNumber=90, createdTime=2022-06-28, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=206be305347e, moduleTitle=Int J Clin Oncol：前期接受醋酸阿比特龙和多西他赛治疗的转移性去势敏感前列腺癌患者的真实结果和风险分层 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=206be305347e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387006, encodeId=847c138e0066e, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Eur Urol：Bempegaldesleukin加Nivolumab用于一线转移性尿路上皮癌效果如何？, objectType=article, longId=730487, objectId=eb89e30487a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb89e30487a4, replyNumber=0, likeNumber=85, createdTime=2022-06-27, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb89e30487a4, moduleTitle=Eur Urol：Bempegaldesleukin加Nivolumab用于一线转移性尿路上皮癌效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb89e30487a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387005, encodeId=4103138e0054b, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=J Clin Oncol：杜瓦鲁单抗联合奥拉帕利治疗初治的转移性尿路上皮癌的疗效和安全性, objectType=article, longId=730446, objectId=7c9fe304466b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c9fe304466b, replyNumber=0, likeNumber=94, createdTime=2022-06-26, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c9fe304466b, moduleTitle=J Clin Oncol：杜瓦鲁单抗联合奥拉帕利治疗初治的转移性尿路上皮癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c9fe304466b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387004, encodeId=79f4138e00472, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Clin Cancer Res：氟维司群联合维奈托克治疗CDK4/6抑制剂难治性ER+转移性乳腺癌, objectType=article, longId=730361, objectId=69abe303613d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69abe303613d, replyNumber=0, likeNumber=86, createdTime=2022-06-25, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69abe303613d, moduleTitle=Clin Cancer Res：氟维司群联合维奈托克治疗CDK4/6抑制剂难治性ER+转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69abe303613d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387007, encodeId=74b4138e0072e, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=JAMA Netw open：转移性肾细胞癌患者“免疫-肿瘤联合治疗”后的影像学反应, objectType=article, longId=730177, objectId=5ba9e3017707, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ba9e3017707, replyNumber=0, likeNumber=93, createdTime=2022-06-23, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ba9e3017707, moduleTitle=JAMA Netw open：转移性肾细胞癌患者“免疫-肿瘤联合治疗”后的影像学反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ba9e3017707)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387003, encodeId=eefe138e003fa, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=J Clin Oncol：强化诱发方案+维持化疗治疗转移性横纹肌肉瘤, objectType=article, longId=729993, objectId=904fe29993ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=904fe29993ee, replyNumber=0, likeNumber=94, createdTime=2022-06-21, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=904fe29993ee, moduleTitle=J Clin Oncol：强化诱发方案+维持化疗治疗转移性横纹肌肉瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=904fe29993ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387002, encodeId=14df138e002a3, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=J Clin Oncol：mFOLFOXIRI+帕尼单抗对比FOLFOX+帕尼单抗一线治疗RAS和BRAF野生型转移性结直肠癌(mCRC)的疗效, objectType=article, longId=729659, objectId=add1e2965928, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=add1e2965928, replyNumber=0, likeNumber=85, createdTime=2022-06-17, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=add1e2965928, moduleTitle=J Clin Oncol：mFOLFOXIRI+帕尼单抗对比FOLFOX+帕尼单抗一线治疗RAS和BRAF野生型转移性结直肠癌(mCRC)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=add1e2965928)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386999, encodeId=95d713869990f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=NEJM Evid：奥拉帕利联合阿比特龙治疗转移性前列腺癌结果公布（PROpel研究）, objectType=article, longId=729571, objectId=1e09e2957129, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e09e2957129, replyNumber=0, likeNumber=108, createdTime=2022-06-16, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e09e2957129, moduleTitle=NEJM Evid：奥拉帕利联合阿比特龙治疗转移性前列腺癌结果公布（PROpel研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e09e2957129)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387001, encodeId=e1c1138e001f9, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Clin Cancer Res：新型PD-L1抗体TQB2450联合安罗替尼治疗局部晚期/转移性软组织肉瘤, objectType=article, longId=729559, objectId=1586e2955944, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1586e2955944, replyNumber=0, likeNumber=94, createdTime=2022-06-16, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1586e2955944, moduleTitle=Clin Cancer Res：新型PD-L1抗体TQB2450联合安罗替尼治疗局部晚期/转移性软组织肉瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1586e2955944)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387000, encodeId=bbba138e000b8, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=J Clin Oncol：mFOLFOXIRI方案联合帕尼单抗治疗RAS/BRAF野生型转移性结直肠癌, objectType=article, longId=729558, objectId=3e05e29558cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e05e29558cc, replyNumber=0, likeNumber=94, createdTime=2022-06-16, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e05e29558cc, moduleTitle=J Clin Oncol：mFOLFOXIRI方案联合帕尼单抗治疗RAS/BRAF野生型转移性结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e05e29558cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386998, encodeId=bdf9138699804, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=NEJM Evid：durvalumab联合标准化疗治疗局部晚期或转移性胆道癌, objectType=article, longId=729496, objectId=5ebee29496b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ebee29496b6, replyNumber=0, likeNumber=84, createdTime=2022-06-15, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ebee29496b6, moduleTitle=NEJM Evid：durvalumab联合标准化疗治疗局部晚期或转移性胆道癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ebee29496b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1387024, encodeId=fd37138e02480, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=2022ASCO丨肺癌，转移性NSCLC领域口头报告摘要汇总, objectType=article, longId=729299, objectId=fe6ce29299c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe6ce29299c3, replyNumber=0, likeNumber=127, createdTime=2022-06-15, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe6ce29299c3, moduleTitle=2022ASCO丨肺癌，转移性NSCLC领域口头报告摘要汇总, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe6ce29299c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386997, encodeId=3caa138699ed7, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Lancet Oncol：卡博替尼联合阿托珠单抗治疗转移性去势抵抗性前列腺癌, objectType=article, longId=729045, objectId=c007e2904512, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c007e2904512, replyNumber=0, likeNumber=108, createdTime=2022-06-11, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c007e2904512, moduleTitle=Lancet Oncol：卡博替尼联合阿托珠单抗治疗转移性去势抵抗性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c007e2904512)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386996, encodeId=2a6313869964e, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Lancet Oncol：FOLFOXIRI联合贝伐单抗±阿替利珠单抗治疗转移性结直肠癌, objectType=article, longId=728685, objectId=6d07e286855f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d07e286855f, replyNumber=0, likeNumber=88, createdTime=2022-06-07, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d07e286855f, moduleTitle=Lancet Oncol：FOLFOXIRI联合贝伐单抗±阿替利珠单抗治疗转移性结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d07e286855f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386993, encodeId=c01513869930a, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=ASCO2022: 中间临床终点作为转移性激素敏感前列腺癌患者总生存期替代指标的科学性分析, objectType=article, longId=728378, objectId=9bf0e283789c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bf0e283789c, replyNumber=0, likeNumber=79, createdTime=2022-06-02, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bf0e283789c, moduleTitle=ASCO2022: 中间临床终点作为转移性激素敏感前列腺癌患者总生存期替代指标的科学性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9bf0e283789c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386990, encodeId=c0d51386990ae, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=2022 ASCO: 筛查、早期治疗和转移性治疗对降低乳腺癌死亡率的影响, objectType=article, longId=728365, objectId=6905e2836591, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6905e2836591, replyNumber=0, likeNumber=96, createdTime=2022-06-02, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6905e2836591, moduleTitle=2022 ASCO: 筛查、早期治疗和转移性治疗对降低乳腺癌死亡率的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6905e2836591)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

转移性

2020-05-29

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Gastroenterology Report：术前CA125升高与接受原发性肿瘤切除的转移性结直肠癌患者的低生存率相关

2022-07-19

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Eur Urol Oncol：雄激素剥夺疗法联合根治性局部治疗与单独的雄激素剥夺疗法治疗新诊断寡转移性前列腺癌的疗效比较

2022-07-18

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Radiology：CT和CA19-9对非转移性胰腺癌治疗效果的评估

2022-07-11

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

J Immunother Cancer：抗PD1±抗CTLA4治疗BRAF/MEK抑制剂治疗失败的V600BRAF突变型转移性黑色素瘤

2022-07-10

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Int J Clin Oncol：前期接受醋酸阿比特龙和多西他赛治疗的转移性去势敏感前列腺癌患者的真实结果和风险分层

2022-06-28

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Eur Urol：Bempegaldesleukin加Nivolumab用于一线转移性尿路上皮癌效果如何？

2022-06-27

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

J Clin Oncol：杜瓦鲁单抗联合奥拉帕利治疗初治的转移性尿路上皮癌的疗效和安全性

2022-06-26

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Clin Cancer Res：氟维司群联合维奈托克治疗CDK4/6抑制剂难治性ER+转移性乳腺癌

2022-06-25

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

JAMA Netw open：转移性肾细胞癌患者“免疫-肿瘤联合治疗”后的影像学反应

2022-06-23

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

J Clin Oncol：强化诱发方案+维持化疗治疗转移性横纹肌肉瘤

2022-06-21

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

J Clin Oncol：mFOLFOXIRI+帕尼单抗对比FOLFOX+帕尼单抗一线治疗RAS和BRAF野生型转移性结直肠癌(mCRC)的疗效

2022-06-17

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

NEJM Evid：奥拉帕利联合阿比特龙治疗转移性前列腺癌结果公布（PROpel研究）

2022-06-16

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Clin Cancer Res：新型PD-L1抗体TQB2450联合安罗替尼治疗局部晚期/转移性软组织肉瘤

2022-06-16

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

J Clin Oncol：mFOLFOXIRI方案联合帕尼单抗治疗RAS/BRAF野生型转移性结直肠癌

2022-06-16

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

NEJM Evid：durvalumab联合标准化疗治疗局部晚期或转移性胆道癌

2022-06-15

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

2022ASCO丨肺癌，转移性NSCLC领域口头报告摘要汇总

2022-06-15

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Lancet Oncol：卡博替尼联合阿托珠单抗治疗转移性去势抵抗性前列腺癌

2022-06-11

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Lancet Oncol：FOLFOXIRI联合贝伐单抗±阿替利珠单抗治疗转移性结直肠癌

2022-06-07

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

ASCO2022: 中间临床终点作为转移性激素敏感前列腺癌患者总生存期替代指标的科学性分析

2022-06-02

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

2022 ASCO: 筛查、早期治疗和转移性治疗对降低乳腺癌死亡率的影响

2022-06-02

科室
- - 订阅+
  - 更多科室
工具
服务